1. Home
  2. CSR vs ABCL Comparison

CSR vs ABCL Comparison

Compare CSR & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo D/B/A Centerspace

CSR

D/B/A Centerspace

N/A

Current Price

$67.00

Market Cap

1.1B

Sector

Real Estate

ML Signal

N/A

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

N/A

Current Price

$4.58

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CSR
ABCL
Founded
1970
2012
Country
United States
Canada
Employees
349
562
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CSR
ABCL
Price
$67.00
$4.58
Analyst Decision
Hold
Strong Buy
Analyst Count
6
5
Target Price
$69.80
$8.40
AVG Volume (30 Days)
81.9K
8.4M
Earning Date
05-04-2026
05-11-2026
Dividend Yield
4.58%
N/A
EPS Growth
N/A
10.91
EPS
N/A
N/A
Revenue
N/A
$75,128,000.00
Revenue This Year
$1.24
N/A
Revenue Next Year
$2.72
$21.85
P/E Ratio
$62.27
N/A
Revenue Growth
N/A
160.56
52 Week Low
$52.76
$1.94
52 Week High
$69.61
$6.52

Technical Indicators

Market Signals
Indicator
CSR
ABCL
Relative Strength Index (RSI) 53.00 56.58
Support Level $64.52 $3.45
Resistance Level $68.33 $4.84
Average True Range (ATR) 1.86 0.39
MACD -0.34 -0.06
Stochastic Oscillator 48.91 41.95

Price Performance

Historical Comparison
CSR
ABCL

About CSR D/B/A Centerspace

Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: